SMi Group announces the 10th Annual RNA Therapeutics Conference

SMi Group20 - 21 February 2019, London, UK.
Undoubtedly, the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.

Join the 10th Annual RNA Therapeutics Conference in February 2019, for SMi's 10th annual sell out event. Bringing together industry experts from leading RNA companies, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing.

Network and learn from key opinion leaders such as:

Chairs for 2019

  • Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
  • Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca

Guest Speakers

  • Carsten Rudolf, Chief Executive Officer, EthrisGmbh
  • Paul Agris, Founder and Director, The RNA Institute

Keynote Speakers

  • Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck & Co, inc.
  • David Giljohan, CEO, Exicure
  • Ingmar Hoerr, Founder & CEO, CureVac AG
  • David Blakey, Chief Scientific Officer, MiNA Therapeutics
  • André Gerber, Professor of RNA Biology, University of Surrey
  • Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals
  • Markus Mandler, Chief Scientific Officer, Accanis Biotech
  • Troels Koch, Vice President & Head of Research, RNA Therapeutics, Roche
  • Hans Kistemaker, Associate Director, ProQR

2019 Featured Highlights

  • Discover the clinical progress of Spherical Nucleic Acids at Exicure
  • Understand Sanofi's strategies to deliver therapeutic oligonucleotides across biobarriers
  • Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets
  • Explore the development of small activating RNA - from bench to bedside with MiNA Therapeutics
  • Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK

For further information and to register, please visit:
http://www.therapeutics-rna.com/wpn

Early-Bird Rates

  • Register by 31st October and save £400
  • Register by 30th November and save £200
  • Register by 15th December and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...